Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.35 |
| ▸ | MAPT | P10636 | 2/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.34 |
| ▸ | CSNK2B | P67870 | 1/20 | 0.34 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.34 |
| ▸ | USP5 | P45974 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | CASP1 | P29466 | 1/20 | 0.34 |
| ▸ | CASP7 | P55210 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18258606 | 1.00 | HSD17B10 (0.42) | HSD17B10NPSR1TP53ALDH1A1KDM4E | |
| Monoethanolamine SCHEMBL18979869 | 0.85 | GABRR1 (0.39) | HSD17B10NPSR1TP53ALDH1A1KMT2A | |
| SCHEMBL27551712 | 0.80 | MAPT (0.35) | HSD17B10NPSR1TP53KMT2AMAPT | |
| SCHEMBL14248374 | 0.77 | RAB9A (0.39) | HSD17B10NPSR1TP53KMT2AMAPT | |
| SCHEMBL14247750 | 0.77 | RAB9A (0.39) | HSD17B10NPSR1TP53KMT2AMAPT | |
| SCHEMBL18258607 | 0.77 | RAB9A (0.39) | HSD17B10NPSR1TP53KMT2AMAPT | |
| SCHEMBL7549988 | 0.76 | MEN1 (0.40) | HSD17B10NPSR1KDM4EKMT2AMAPT | |
| SCHEMBL498341 | 0.74 | HSD17B10 (0.43) | HSD17B10NPSR1GAA | |
| SCHEMBL7936004 | 0.72 | HSD17B10 (0.42) | HSD17B10NPSR1TP53GAA | |
| SCHEMBL20542719 | 0.72 | KDM4E (0.42) | NPSR1ALDH1A1KDM4EKMT2AUSP5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 210 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3615559-B1 | MODIFIED COMPLEMENT PROTEINS AND USES THEREOF | UNIV NEWCASTLE (GB) | 2025-06-18 | — | — | EP | claimed |
| US-20240012011-A1 | METHODS AND ASSAYS FOR SECRETOME ACTIVITY ANALYSIS | OXFORD FINANCE LLC | 2024-01-11 | — | — | US | claimed |
| US-10987408-B2 | Compositions and methods for modulating toll-like receptor 2 activation | THE CLEVELAND CLINIC FOUNDATION (US) | 2021-04-27 | — | — | US | claimed |
| EP-3615559-A1 | MODIFIED COMPLEMENT PROTEINS AND USES THEREOF | University of Newcastle Upon Tyne (GB) | 2020-03-04 | — | — | EP | claimed |
| CN-108743980-A | A kind of folate-targeted visualization photo-thermal-chemotherapeutant and preparation method thereof | 重庆医科大学 | 2018-11-06 | — | — | CN | claimed |
| WO-2018197873-A1 | MODIFIED COMPLEMENT PROTEINS AND USES THEREOF | UNIVERSITY OF NEWCASTLE UPON TYNE (GB) | 2018-11-01 | — | — | WO | claimed |
| US-20180280482-A1 | COMPOSITIONS AND METHODS FOR MODULATING TOLL-LIKE RECEPTOR 2 ACTIVATION | CLEVELAND CLINIC FOUND (US) | 2018-10-04 | — | — | US | claimed |
| US-9981018-B2 | Compositions and methods for modulating toll-like receptor 2 activation | THE CLEVELAND CLINIC FOUNDATION (US) | 2018-05-29 | — | — | US | claimed |
| US-9957333-B2 | Anti-CEP antibody or fragment thereof | CASE WESTERN RESERVE UNIVERSITY (US) | 2018-05-01 | — | — | US | claimed |
| CN-104662004-B | Novel rebamipide prodrug, method for producing same, and usage thereof | 三进制药株式会社 | 2017-04-19 | — | — | CN | claimed |
| US-8664470-B2 | Mouse model of retinal degeneration | THE CLEVELAND CLINIC FOUNDATION (US) | 2014-03-04 | — | — | US | claimed |
| WO-2013142362-A1 | REGULATOR OF COMPLEMENT ACTIVATION AND USES THEREOF | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2013-09-26 | — | — | WO | claimed |
| EP-2049156-B1 | COMPOSITIONS AND METHODS FOR MACULAR DEGENERATION | CLEVELAND CLINIC FOUNDATION (US) | 2013-09-25 | — | — | EP | claimed |
| US-20120230996-A1 | Compositions And Methods For Macular Degeneration | The Cleveland Clinic Foundation and Case Western Reserve University (US) | 2012-09-13 | — | — | US | claimed |
| US-8137991-B2 | Methods of reducing angiogenesis of age-related macular degeneration (AMD) or choroidal neovascularization by an anti-carboxyetheylpyrrole (CFP) antibody | THE CLEVELAND CLINIC FOUNDATION (US) | 2012-03-20 | — | — | US | claimed |
| US-20100143380-A1 | COMPOSITIONS AND METHODS FOR MACULAR DEGENERATION | CLEVELAND CLINIC FOUNDATION, THE | 2010-06-10 | — | — | US | claimed |
| US-20090155243-A1 | NON-HUMAN MODEL OF AUTOIMMUNE DISEASE | THE CLEVELAND CLINIC FOUNDATION (US) | 2009-06-18 | — | — | US | claimed |
| EP-2049156-A2 | COMPOSITIONS AND METHODS FOR MACULAR DEGENERATION | The Cleveland Clinic Foundation (US) | 2009-04-22 | — | — | EP | claimed |
| WO-2008013797-A2 | COMPOSITIONS AND METHODS FOR MACULAR DEGENERATION | THE CLEVELAND CLINIC FOUNDATION (US) | 2008-01-31 | — | — | WO | claimed |
| WO-2007127151-A2 | NON-HUMAN MODEL OF AUTOIMMUNE DISEASE | THE CLEVELAND CLINIC FOUNDATION (US) | 2007-11-08 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10987408-B2 | Compositions and methods for modulating toll-like receptor 2 activation | TLR2, TLR3, TLR1 | HSD17B10 2405/4885NPSR1 484/4885TP53 2587/4885 |
| US-20180280482-A1 | COMPOSITIONS AND METHODS FOR MODULATING TOLL-LIKE RECEPTOR 2 ACTIVATION | TLR2, TLR3, TLR1 | HSD17B10 2405/4885NPSR1 484/4885TP53 2587/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.